Sunesis to Present at ROTH 23rd Annual OC Growth Stock Conference
SOUTH SAN FRANCISCO, Calif., Mar 9, 2011 (GlobeNewswire via COMTEX) --
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Senior Vice President of Corporate Development & Finance and Chief Financial Officer, Eric Bjerkholt, will be presenting at the ROTH 23rd Annual OC Growth Stock Conference on Monday, March 14th at 3:30 PM Pacific Time (6:30 PM Eastern Time), at The Ritz Carlton in Laguna Niguel, California. This presentation will not be webcast.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
The Sunesis Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8773
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Sunesis Pharmaceuticals, Inc.
CONTACT: Andrea Rabney Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717